Related Experiment Video
Updated: Feb 6, 2026

SA-β-Galactosidase-Based Screening Assay for the Identification of Senotherapeutic Drugs
Published on: June 28, 2019
Newborn screening for cerebrotendinous xanthomatosis is the solution for early identification and treatment
Andrea E DeBarber1, Limor Kalfon2, Ayalla Fedida2,3
1Physiology and Pharmacology Department, Oregon Health and Science University (OHSU), Portland, OR debarber@ohsu.edu falikmd.genetics@gmail.com.
Insights
Newborn screening for Cerebrotendinous xanthomatosis (CTX) using a two-tier dried bloodspot test shows high accuracy. Early CTX detection enables effective treatment, preventing disease progression.
Area of Science:
- Biochemistry
- Genetics
- Neonatal screening
Background:
- Cerebrotendinous xanthomatosis (CTX) is a rare, progressive metabolic leukodystrophy.
- Delayed diagnosis of CTX often hinders effective early intervention, impacting patient outcomes.
- Identifying CTX at birth is crucial for a functional cure.
Purpose of the Study:
- To evaluate a two-tier dried bloodspot (DBS) screening test for Cerebrotendinous xanthomatosis (CTX) in a high-risk Israeli newborn population.
- To identify CTX-causing founder genetic variants within specific ethnic groups.
- To assess the feasibility of newborn screening for CTX.
Main Methods:
- Pilot study involving archived and prospectively collected newborn DBS samples.
- First-tier screening using flow injection analysis-tandem mass spectrometry (FIA-MS/MS).
- Second-tier confirmation using liquid chromatography-tandem mass spectrometry (LC-MS/MS).
- Analysis of CYP27A1 gene variants in Druze and Moroccan Jewish populations.
Main Results:
- The two-tier DBS test demonstrated 100% sensitivity for CTX detection.
- FIA-MS/MS showed a low false-positive rate (0.1-0.5%), while LC-MS/MS achieved 0% false positives (100% specificity).
- 5β-cholestane-3α,7α,12α,25-tetrol-3-O-β-D-glucuronide was identified as the primary bile-alcohol marker.
- A 1:30 carriership frequency for the c.355delC CYP27A1 variant was found in Druze newborns, estimating CTX prevalence at 1:3,600.
Conclusions:
- A two-tier DBS screening approach is feasible for early detection of CTX in newborns.
- The study identified specific genetic variants and disease markers relevant to the screened population.
- Findings support the implementation of large-scale prospective pilot studies for CTX newborn screening.
Abstract:
Cerebrotendinous xanthomatosis (CTX) is a progressive metabolic leukodystrophy. Early identification and treatment from birth onward effectively provides a functional cure, but diagnosis is often delayed. We conducted a pilot study using a two-tier test for CTX to screen archived newborn dried bloodspots (DBSs) or samples collected prospectively from a high-risk Israeli newborn population. All DBS samples were analyzed with flow injection analysis (FIA)-MS/MS, and 5% of samples were analyzed with LC-MS/MS. Consecutively collected samples were analyzed to identify CTX-causing founder genetic variants common among Druze and Moroccan Jewish populations. First-tier analysis with FIA-MS/MS provided 100% sensitivity to detect CTX-positive newborn DBSs, with a low false-positive rate (0.1-0.5%). LC-MS/MS, as a second-tier test, provided 100% sensitivity to detect CTX-positive newborn DBSs with a false-positive rate of 0% (100% specificity). In addition, 5β-cholestane-3α,7α,12α,25-tetrol-3-O-β-D-glucuronide was identified as the predominant bile-alcohol disease marker present in CTX-positive newborn DBSs. In newborns identifying as Druze, a 1:30 carriership frequency was determined for the c.355delC CYP27A1 gene variant, providing an estimated disease prevalence of 1:3,600 in this population. These data support the feasibility of two-tier DBS screening for CTX in newborns and set the stage for large-scale prospective pilot studies.
Related Concept Videos
Ideal Solutions
General Properties of Solutions
Solution Formation
This selective...
Enthalpy of Solution
Standard Solutions
Blank Solutions
In some experimental cases, the reagents, solvents, or lab equipment used in...

